ROIV
Roivant Sciences Ltd
NASDAQ: ROIV · HEALTHCARE · BIOTECHNOLOGY
$27.52
-0.90% today
Updated 2026-04-29
Market cap
$19.70B
P/E ratio
—
P/S ratio
1,479.80x
EPS (TTM)
$-1.17
Dividend yield
—
52W range
$11 – $30
Volume
5.5M
Roivant Sciences Ltd (ROIV) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.32M | $67.69M | $23.80M | $55.29M | $61.28M | $32.71M | $29.05M |
| Revenue growth (YoY) | — | +2812.6% | -64.8% | +132.3% | +10.8% | -46.6% | -11.2% |
| Cost of revenue | $606000.00 | $1.13M | $2.06M | $8.97M | $13.13M | $1.60M | $911000.00 |
| Gross profit | $1.72M | $66.56M | $21.74M | $46.32M | $48.15M | $31.11M | $28.14M |
| Gross margin | 73.9% | 98.3% | 91.4% | 83.8% | 78.6% | 95.1% | 96.9% |
| R&D | $512.99M | $263.22M | $236.63M | $483.04M | $525.22M | $439.91M | $550.41M |
| SG&A | $237.21M | $335.77M | $259.88M | $775.03M | $600.51M | $416.13M | $591.41M |
| Operating income | $-748.49M | $-532.42M | $-1.07B | $-1.35B | $-1.18B | $4.50B | $-1.00B |
| Operating margin | -32207.0% | -786.6% | -4500.5% | -2444.8% | -1917.9% | 13746.9% | -3453.3% |
| EBITDA | $138.13M | $-553.30M | $-720.58M | $-910.77M | $-1.18B | $-802.89M | $-1.10B |
| EBITDA margin | 5943.5% | -817.4% | -3028.3% | -1647.4% | -1922.3% | -2454.4% | -3784.8% |
| EBIT | $-610.36M | $-532.42M | $-895.74M | $-916.71M | $-1.20B | $-824.93M | $-1.11B |
| Interest expense | $7.54M | $7.68M | $2.81M | $7.04M | $27.97M | $34.78M | — |
| Income tax | $2.62M | $7.12M | $1.69M | $369000.00 | $5.19M | $21.50M | $48.17M |
| Effective tax rate | -0.3% | 0.6% | -0.2% | -0.0% | -0.5% | 0.5% | -38.9% |
| Net income | $-1.04B | $1.20B | $-809.23M | $-845.26M | $-1.01B | $4.35B | $-171.98M |
| Net income growth (YoY) | — | +215.2% | -167.4% | -4.5% | -19.4% | +531.0% | -104.0% |
| Profit margin | -44835.2% | 1773.6% | -3400.9% | -1528.9% | -1646.6% | 13294.2% | -592.0% |